Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET: An equilibrium approach

NeuroImage

Volumn 24, Issue 4, 2005, Pages 1192-1204

  Meyer, Philipp T ^a   Elmenhorst, David ^a   Bier, Dirk ^a   Holschbach, Marcus H ^a   Matusch, Andreas ^a   Coenen, Heinz H ^a   Zilles, Karl ^a   Bauer, Andreas ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

A1 adenosine receptor; Equilibrium analysis; Kinetic modeling; Positron emission tomography

Indexed keywords

8 CYCLOPENTYL 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE F 18; ADENOSINE A1 RECEPTOR; UNCLASSIFIED DRUG; XANTHINE DERIVATIVE; 8 CYCLOPENTA 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE; 8-CYCLOPENTA-3-(3-FLUOROPROPYL)-1-PROPYLXANTHINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ANALYTICAL ERROR; ARTERY; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; HUMAN; INFUSION; MALE; NEUROIMAGING; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VEIN; ALGORITHM; BIOLOGICAL MODEL; BRAIN; BRAIN LEVEL; FEMALE; HISTOLOGY; IMAGE PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; ALGORITHMS; BRAIN; BRAIN CHEMISTRY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; KINETICS; LINEAR MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, ADENOSINE A1; XANTHINES;

EID: 12844272312     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2004.10.029     Document Type: Article

References (56)

1. A. Abi-Dargham, M. Laruelle, J. Seibyl, Z. Rattner, R.M. Baldwin, S.S. Zoghbi, Y. Zea-Ponce, J.D. Bremner, T.M. Hyde, D.S. Charney, P.B. Hoffer, and R.B. Innis SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms J. Nucl. Med. 35 1994 228 238
2. A. Abi-Dargham, N. Simpson, L. Kegeles, R. Parsey, D.R. Hwang, S. Anjilvel, Y. Zea-Ponce, I. Lombardo, R. Van Heertum, J.J. Mann, C. Foged, C. Halldin, and M. Laruelle PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756 Synapse 32 1999 93 109
3. A. Bauer, M.H. Holschbach, P.T. Meyer, C. Boy, H. Herzog, R.A. Olsson, H.H. Coenen, and K. Zilles In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography NeuroImage 19 2003 1760 1769
4. A. Bauer, M.H. Holschbach, M. Cremer, S. Weber, C. Boy, N.J. Shah, R.A. Olsson, H. Halling, H.H. Coenen, and K. Zilles Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET J. Nucl. Med. 44 2003 1682 1689
5. F. Berthou, T. Goasduff, Y. Dreano, and J.F. Menez Caffeine increases its own metabolism through cytochrome P4501A induction in rats Life Sci. 57 1995 541 549
6. R.A. Bressan, K. Erlandsson, R.S. Mulligan, R.N. Gunn, V.J. Cunningham, J. Owens, I.D. Cullum, P.J. Ell, and L.S. Pilowsky A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [(123)i]CNS 1261 Nucl. Med. Biol. 31 2004 155 164
7. C. Burger, and A. Buck Requirements and implementation of a flexible kinetic modeling tool J. Nucl. Med. 38 1997 1818 1823
8. J.A. Carrillo, and J. Benitez Clinically significant pharmacokinetic interactions between dietary caffeine and medications Clin. Pharmacokinet. 39 2000 127 153
9. J.A. Carrillo, M. Christensen, S.I. Ramos, C. Alm, M.L. Dahl, J. Benitez, and L. Bertilsson Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine Ther. Drug Monit. 22 2000 409 417
10. R. Carson PET physiological measurements using constant infusion Nucl. Med. Biol. 27 2000 657 660
11. R.E. Carson, M.A. Channing, R.G. Blasberg, B.B. Dunn, R.M. Cohen, K.C. Rice, and P. Herscovitch Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography J. Cereb. Blood Flow Metab. 13 1993 24 42
12. R.E. Carson, A. Breier, A. de Bartolomeis, R.C. Saunders, T.P. Su, B. Schmall, M.G. Der, D. Pickar, and W.C. Eckelman Quantification of amphetamine-induced changes in [11C]raclopride binding with continuous infusion J. Cereb. Blood Flow Metab. 17 1997 437 447
13. W.G. Chung, J.H. Kang, C.S. Park, M.H. Cho, and Y.N. Cha Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism Clin. Pharmacol. Ther. 67 2000 258 266
14. R.A. Cunha Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors Neurochem. Int. 38 2001 107 125
15. J. Deckert, F. Abel, G. Kunig, J. Hartmann, D. Senitz, H. Maier, G. Ransmayr, and P. Riederer Loss of human hippocampal adenosine A1 receptors in dementia: evidence for lack of specificity Neurosci. Lett. 244 1998 1 4
16. T.V. Dunwiddie, and S.A. Masino The role and regulation of adenosine in the central nervous system Annu. Rev. Neurosci. 24 2001 31 55
17. C.J. Endres, B.S. Kolachana, R.C. Saunders, T. Su, D. Weinberger, A. Breier, W.C. Eckelman, and R.E. Carson Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies J. Cereb. Blood Flow Metab. 17 1997 932 942
18. M. Fujita, J.P. Seibyl, N.P. Verhoeff, M. Ichise, R.M. Baldwin, S.S. Zoghbi, C. Burger, J.K. Staley, N. Rajeevan, D.S. Charney, and R.B. Innis Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors Synapse 34 1999 290 304
19. M. Fujita, N.P. Verhoeff, A. Varrone, S.S. Zoghbi, R.M. Baldwin, P.A. Jatlow, G.M. Anderson, J.P. Seibyl, and R.B. Innis Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans Eur. J. Pharmacol. 387 2000 179 188
20. M. Fujita, M.S. Al-Tikriti, G. Tamagnan, S.S. Zoghbi, A. Bozkurt, R.M. Baldwin, and R.B. Innis Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380 Synapse 48 2003 116 122
21. M. Glass, R.L. Faull, J.Y. Bullock, K. Jansen, E.W. Mee, E.B. Walker, B.J. Synek, and M. Dragunow Loss of A1 adenosine receptors in human temporal lobe epilepsy Brain Res. 710 1996 56 68
22. N. Gouder, J.M. Fritschy, and D. Boison Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy Epilepsia 44 2003 877 885
23. H.L. Haas, and O. Selbach Functions of neuronal adenosine receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 362 2000 375 381
24. J.E. Holden, S. Jivan, T.J. Ruth, and D.J. Doudet In vivo receptor assay with multiple ligand concentrations: an equilibrium approach J. Cereb. Blood Flow Metab. 22 2002 1132 1141
25. M.H. Holschbach, T. Fein, C. Krummeich, R.G. Lewis, W. Wutz, U. Schwabe, D. Unterlugauer, and R.A. Olsson A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET) J. Med. Chem. 41 1998 555 563
26. M.H. Holschbach, R.A. Olsson, D. Bier, W. Wutz, W. Sihver, M. Schuller, B. Palm, and H.H. Coenen Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging J. Med. Chem. 45 2002 5150 5156
27. H. Ito, M. Koyama, R. Goto, R. Kawashima, S. Ono, H. Atsumi, K. Ishii, and H. Fukuda Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling J. Nucl. Med. 36 1995 2339 2342
28. H. Ito, J. Hietala, G. Blomqvist, C. Halldin, and L. Farde Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding J. Cereb. Blood Flow Metab. 18 1998 941 950
29. J.W. Jefferson Drug and diet interactions: avoiding therapeutic paralysis J. Clin. Psychiatry 59 Suppl. 16 1998 31 39 (discussion 40-42)
30. R. Joeres, H. Klinker, H. Heusler, J. Epping, W. Zilly, and E. Richter Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis Hepatology 8 1988 575 579
31. L. Kaijser, and S. Rossner Removal of exogenous triglycerides in human forearm muscle and subcutaneous tissue Acta Med. Scand. 197 1975 289 294
32. R.A. Koeppe, K.A. Frey, A. Kume, R. Albin, M.R. Kilbourn, and D.E. Kuhl Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography J. Cereb. Blood Flow Metab. 17 1997 919 931
33. M. Laruelle, A. Abi-Dargham, Z. Rattner, M.S. al-Tikriti, Y. Zea-Ponce, S.S. Zoghbi, D.S. Charney, J. Price, J.J. Frost, P.B. Hoffer, R.M. Baldwin, and R.B. Innis Single photon emission tomography measurement of benzodiazepine receptor number and affinity in primate brain: a constant infusion paradigm with [123I]iomazenil Eur. J. Pharmacol. 230 1993 119 123
34. M. Laruelle, A. Abi-Dargham, M.S. al-Tikriti, R.M. Baldwin, Y. Zea-Ponce, S.S. Zoghbi, D.S. Charney, P.B. Hoffer, and R.B. Innis SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters J. Cereb. Blood Flow Metab. 14 1994 453 465
35. M. Laruelle, M.S. al-Tikriti, Y. Zea-Ponce, S.S. Zoghbi, R.M. Baldwin, D.S. Charney, P.B. Hoffer, H.F. Kung, and R.B. Innis In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography Eur. J. Pharmacol. 263 1994 39 51
36. M. Laruelle, A. Abi-Dargham, C.H. van Dyck, W. Rosenblatt, Y. Zea-Ponce, S.S. Zoghbi, R.M. Baldwin, D.S. Charney, P.B. Hoffer, H.F. Kung, and R.B. Innis SPECT imaging of striatal dopamine release after amphetamine challenge J. Nucl. Med. 36 1995 1182 1190
37. M. Laruelle, R.N. Iyer, M.S. al-Tikriti, Y. Zea-Ponce, R. Malison, S.S. Zoghbi, R.M. Baldwin, H.F. Kung, D.S. Charney, P.B. Hoffer, R.B. Innis, and C.W. Bradberry Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates Synapse 25 1997 1 14
38. J. Logan, J.S. Fowler, N.D. Volkow, A.P. Wolf, S.L. Dewey, D.J. Schlyer, R.R. MacGregor, R. Hitzemann, B. Bendriem, S.J. Gatley, and D.R. Christman Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects J. Cereb. Blood Flow Metab. 10 1990 740 747
39. J. Logan, J.S. Fowler, N.D. Volkow, Y.S. Ding, G.J. Wang, and D.L. Alexoff A strategy for removing the bias in the graphical analysis method J. Cereb. Blood Flow Metab. 21 2001 307 320
40. H.G. Mandel Update on caffeine consumption, disposition and action Food Chem. Toxicol. 40 2002 1231 1234
41. D. Martinez, M. Slifstein, A. Broft, O. Mawlawi, D.R. Hwang, Y. Huang, T. Cooper, L. Kegeles, E. Zarahn, A. Abi-Dargham, S.N. Haber, and M. Laruelle Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum J. Cereb. Blood Flow Metab. 23 2003 285 300
42. P.T. Meyer, D. Bier, M.H. Holschbach, M. Cremer, L. Tellmann, and A. Bauer In vivo imaging of rat brain A1 adenosine receptor occupancy by caffeine Eur. J. Nucl. Med. Mol. Imaging 30 2003 1440
43. P.T. Meyer, D. Bier, M.H. Holschbach, C. Boy, R.A. Olsson, H.H. Coenen, K. Zilles, and A. Bauer Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET J. Cereb. Blood Flow Metab. 24 2004 323 333
44. E.L. Michalets Update: clinically significant cytochrome P-450 drug interactions Pharmacotherapy 18 1998 84 112
45. M.A. Mintun, M.E. Raichle, M.R. Kilbourn, G.F. Wooten, and M.J. Welch A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography Ann. Neurol. 15 1984 217 227
46. U. Pietrzyk, K. Herholz, G. Fink, A. Jacobs, R. Mielke, I. Slansky, M. Wurker, and W.D. Heiss An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies J. Nucl. Med. 35 1994 2011 2018
47. L.H. Pinborg, K.H. Adams, C. Svarer, S. Holm, S.G. Hasselbalch, S. Haugbol, J. Madsen, and G.M. Knudsen Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach J. Cereb. Blood Flow Metab. 23 2003 985 996
48. T. Porkka-Heiskanen, L. Alanko, A. Kalinchuk, and D. Stenberg Adenosine and sleep Sleep Med. Rev. 6 2002 321 332
49. V. Ramkumar, D.M. Hallam, and Z. Nie Adenosine, oxidative stress and cytoprotection Jpn. J. Pharmacol. 86 2001 265 274
50. D. Shi, and J.W. Daly Chronic effects of xanthines on levels of central receptors in mice Cell. Mol. Neurobiol. 19 1999 719 732
51. M. Slifstein, and M. Laruelle Effects of statistical noise on graphic analysis of PET neuroreceptor studies J. Nucl. Med. 41 2000 2083 2088
52. I. Tantcheva-Poor, M. Zaigler, S. Rietbrock, and U. Fuhr Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test Pharmacogenetics 9 1999 131 144 (Erratum in: Pharmacogenetics 1999;9,781)
53. R.J. Turesky, J. Richoz, A. Constable, K.D. Curtis, K.H. Dingley, and K.W. Turteltaub The effects of coffee on enzymes involved in metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in rats Chem.-Biol. Interact. 145 2003 251 265
54. J. Ulas, L.C. Brunner, L. Nguyen, and C.W. Cotman Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study Neuroscience 52 1993 843 854
55. C.H. van Dyck, P.Z. Tan, R.M. Baldwin, L.A. Amici, P.K. Garg, C.K. Ng, R. Soufer, D.S. Charney, and R.B. Innis PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [18F]altanserin J. Nucl. Med. 41 2000 234 241
56. H. Watabe, C.J. Endres, A. Breier, B. Schmall, W.C. Eckelman, and R.E. Carson Measurement of dopamine release with continuous infusion of [11C]raclopride: optimization and signal-to-noise considerations J. Nucl. Med. 41 2000 522 530